AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018
Jan 25, 2018
31580_dirs_2018-01-25_2123c6d5-26e1-4a51-8683-dfa018be2b94.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-01-23
Reporting Person: Hoerter Steven L. (Chief Commercial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-01-23 | Stock option (right to buy) | $39.76 | M | 25000 | Disposed | 2016-02-15 | Common stock (25000) | Direct |
Footnotes
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The original Form 4, filed on January 25, 2018, stated that 25,000 derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of 25,000 derivative securities. This Form 4 amendment is to solely to correct the nature of the transaction.
F3: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.